-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Traditional Chinese medicine refers to the collection, processing and preparation of traditional Chinese medicine theory to guide the collection, processing and preparation, to explain the mechanism of action, and to guide clinical application
.
At the same time, it is also a substance that is used to prevent, treat and diagnose diseases under the guidance of traditional Chinese medicine theory and has the functions of rehabilitation and health care
.
In recent years, under the background that the national policy strongly encourages and supports the development of traditional Chinese medicine, as well as the accelerated aging process of the population and the vigorous development of the health service industry, people's demand for the traditional Chinese medicine industry is becoming more and more vigorous
.
With the continuous expansion of demand, the traditional Chinese medicine market has also begun to continue to grow
.
In addition, it is worth mentioning that in terms of innovative traditional Chinese medicine drugs, the number of approvals has also begun to show a blowout trend
.
For example, in 2021, both the speed of approval and the number of approvals for innovative traditional Chinese medicine drugs will hit a new high
.
According to the current development trend, the industry generally believes that the traditional Chinese medicine industry will maintain a long-term and stable growth in the future and occupy an important position in China's pharmaceutical industry
.
In fact, the current vigorous development of the traditional Chinese medicine industry is inseparable from the catalytic role of policies
.
It is understood that in the past two years, policies to support the development of the Chinese medicine industry have been frequently introduced
.
For example, in 2020, the State Food and Drug Administration issued the "Classification of Traditional Chinese Medicine Registration and Application Materials Requirements", which divided the registration of traditional Chinese medicines into four categories: innovative Chinese medicines (category 1), improved new Chinese medicines, classic prescriptions and drugs with the same name.
The registration classification of traditional Chinese medicines is oriented by clinical value, encourages the inheritance and innovation of traditional Chinese medicines, and further unleashes the innovation potential of traditional Chinese medicines
.
In February 2021, the "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics" pointed out that the reform of the review and approval mechanism of traditional Chinese medicines should be accelerated, and the evidence system of traditional Chinese medicine registration review and evaluation will be established with the "three combinations" of traditional Chinese medicine theory, human experience and clinical trials.
.
The "Measures" take the development of traditional Chinese medicine as the main line, and further strengthen the pertinence, objective and operability of the policy
.
On December 30, 2021, the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine", which increased the guarantee and support for the development of traditional Chinese medicine from the payment side.
.
It can be seen from the continuous introduction of the above measures that the state is vigorously supporting and promoting the development of the traditional Chinese medicine industry, which will also bring greater imagination to the future development of the traditional Chinese medicine industry
.
It is understood that since 2022, many capitals have paid close attention to the traditional Chinese medicine sector due to their optimism about the Chinese medicine market
.
At present, many traditional Chinese medicine companies have recently released relevant investor relations activity record sheets, including Kangenbei, Yiling Pharmaceutical, Xintian Pharmaceutical,
etc.
Among them, the record form of investor relations activities released by Yiling Pharmaceutical on January 20 shows that the company accepted 44 institutional surveys on January 19, 2022
.
In the research activities, the company's future sales growth momentum of Lianhua Qingwen, the overseas listing and sales of Lianhua Qingwen, the next potential sales varieties, and the impact of the centralized procurement of Chinese patent medicines on the company have all been affected by the agency.
's attention
.
.
At the same time, it is also a substance that is used to prevent, treat and diagnose diseases under the guidance of traditional Chinese medicine theory and has the functions of rehabilitation and health care
.
In recent years, under the background that the national policy strongly encourages and supports the development of traditional Chinese medicine, as well as the accelerated aging process of the population and the vigorous development of the health service industry, people's demand for the traditional Chinese medicine industry is becoming more and more vigorous
.
With the continuous expansion of demand, the traditional Chinese medicine market has also begun to continue to grow
.
In addition, it is worth mentioning that in terms of innovative traditional Chinese medicine drugs, the number of approvals has also begun to show a blowout trend
.
For example, in 2021, both the speed of approval and the number of approvals for innovative traditional Chinese medicine drugs will hit a new high
.
According to the current development trend, the industry generally believes that the traditional Chinese medicine industry will maintain a long-term and stable growth in the future and occupy an important position in China's pharmaceutical industry
.
In fact, the current vigorous development of the traditional Chinese medicine industry is inseparable from the catalytic role of policies
.
It is understood that in the past two years, policies to support the development of the Chinese medicine industry have been frequently introduced
.
For example, in 2020, the State Food and Drug Administration issued the "Classification of Traditional Chinese Medicine Registration and Application Materials Requirements", which divided the registration of traditional Chinese medicines into four categories: innovative Chinese medicines (category 1), improved new Chinese medicines, classic prescriptions and drugs with the same name.
The registration classification of traditional Chinese medicines is oriented by clinical value, encourages the inheritance and innovation of traditional Chinese medicines, and further unleashes the innovation potential of traditional Chinese medicines
.
In February 2021, the "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics" pointed out that the reform of the review and approval mechanism of traditional Chinese medicines should be accelerated, and the evidence system of traditional Chinese medicine registration review and evaluation will be established with the "three combinations" of traditional Chinese medicine theory, human experience and clinical trials.
.
The "Measures" take the development of traditional Chinese medicine as the main line, and further strengthen the pertinence, objective and operability of the policy
.
On December 30, 2021, the State Administration of Traditional Chinese Medicine issued the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine", which increased the guarantee and support for the development of traditional Chinese medicine from the payment side.
.
It can be seen from the continuous introduction of the above measures that the state is vigorously supporting and promoting the development of the traditional Chinese medicine industry, which will also bring greater imagination to the future development of the traditional Chinese medicine industry
.
It is understood that since 2022, many capitals have paid close attention to the traditional Chinese medicine sector due to their optimism about the Chinese medicine market
.
At present, many traditional Chinese medicine companies have recently released relevant investor relations activity record sheets, including Kangenbei, Yiling Pharmaceutical, Xintian Pharmaceutical,
etc.
Among them, the record form of investor relations activities released by Yiling Pharmaceutical on January 20 shows that the company accepted 44 institutional surveys on January 19, 2022
.
In the research activities, the company's future sales growth momentum of Lianhua Qingwen, the overseas listing and sales of Lianhua Qingwen, the next potential sales varieties, and the impact of the centralized procurement of Chinese patent medicines on the company have all been affected by the agency.
's attention
.
